JP2008543278A5 - - Google Patents

Info

Publication number

JP2008543278A5

JP2008543278A5 JP2008510449A JP2008510449A JP2008543278A5 JP 2008543278 A5 JP2008543278 A5 JP 2008543278A5 JP 2008510449 A JP2008510449 A JP 2008510449A JP 2008510449 A JP2008510449 A JP 2008510449A JP 2008543278 A5 JP2008543278 A5 JP 2008543278A5

Authority

JP

Japan

Prior art keywords

conjugate

antibody molecule

conjugate according

seq

domain

Prior art date

2006-05-03

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 claims description 12
• 102000013462 Interleukin-12 Human genes 0.000 claims description 10
• 108010065805 Interleukin-12 Proteins 0.000 claims description 10
• 102000004169 proteins and genes Human genes 0.000 claims description 7
• 108090000623 proteins and genes Proteins 0.000 claims description 7
• 230000033115 angiogenesis Effects 0.000 claims description 4
• 108010029485 Protein Isoforms Proteins 0.000 claims description 2
• 102000001708 Protein Isoforms Human genes 0.000 claims description 2
• 102000007000 Tenascin Human genes 0.000 claims description 2
• 108010008125 Tenascin Proteins 0.000 claims description 2
• 102000037865 fusion proteins Human genes 0.000 claims 11
• 108020001507 fusion proteins Proteins 0.000 claims 11
• 125000003275 alpha amino acid group Chemical group 0.000 claims 6
• 239000000203 mixture Substances 0.000 claims 5
• 239000000833 heterodimer Substances 0.000 claims 4
• 238000000034 method Methods 0.000 claims 4
• 102000039446 nucleic acids Human genes 0.000 claims 4
• 108020004707 nucleic acids Proteins 0.000 claims 4
• 150000007523 nucleic acids Chemical class 0.000 claims 4
• 239000002773 nucleotide Substances 0.000 claims 2
• 125000003729 nucleotide group Chemical group 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
• 102000016359 Fibronectins Human genes 0.000 claims 1
• 108010067306 Fibronectins Proteins 0.000 claims 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
• 210000004027 cell Anatomy 0.000 claims 1
• 230000001268 conjugating effect Effects 0.000 claims 1
• 210000002744 extracellular matrix Anatomy 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 239000013598 vector Substances 0.000 claims 1
• 230000001575 pathological effect Effects 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 238000011282 treatment Methods 0.000 description 5
• 206010012689 Diabetic retinopathy Diseases 0.000 description 4
• 206010064930 age-related macular degeneration Diseases 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 201000011066 hemangioma Diseases 0.000 description 4
• 208000002780 macular degeneration Diseases 0.000 description 4
• 206010039073 rheumatoid arthritis Diseases 0.000 description 4
• 230000009870 specific binding Effects 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 3
• 201000010099 disease Diseases 0.000 description 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
• 239000000032 diagnostic agent Substances 0.000 description 2
• 229940039227 diagnostic agent Drugs 0.000 description 2
• 238000002405 diagnostic procedure Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 229940088623 biologically active substance Drugs 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1